vapiprost and Hypertension--Renovascular

vapiprost has been researched along with Hypertension--Renovascular* in 2 studies

Trials

1 trial(s) available for vapiprost and Hypertension--Renovascular

ArticleYear
The haemodynamic effects of GR 32191, a thromboxane A2 receptor antagonist, in patients with renal artery stenosis and hypertension.
    British journal of clinical pharmacology, 1993, Volume: 36, Issue:3

    This study was designed to determine if GR 32191 a thromboxane A2 receptor antagonist, would lower blood pressure in patients with hypertension and renal artery stenosis. Eight patients with unilateral atheromatous renal artery stenosis and hypertension were studied in a double-blind, single dose, placebo controlled, crossover study. The results show that, GR 32191, given orally, in doses of 20 mg and 40 mg, does not reduce the blood pressure to any clinically important degree.

    Topics: Aged; Biphenyl Compounds; Blood Pressure; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemodynamics; Heptanoic Acids; Humans; Hypertension, Renovascular; Male; Middle Aged; Receptors, Thromboxane; Renal Artery Obstruction

1993

Other Studies

1 other study(ies) available for vapiprost and Hypertension--Renovascular

ArticleYear
The role of thromboxane in two-kidney, one-clip Goldblatt hypertension in rats.
    The American journal of physiology, 1989, Volume: 257, Issue:2 Pt 2

    Impaired contralateral kidney (CLK) function is important in the maintenance of hypertension in the two-kidney, one-clip (2K, 1C) Goldblatt rat model. Since glomerular filtration rate (GFR) is influenced by the products of arachidonic acid metabolism, we investigated the potential role of eicosanoids as mediators of impaired CLK pressure-volume regulation. At 4 wk following right renal artery clipping, GFR of hypertensive rats was significantly reduced. This decrease was due to the fixed reduction in GFR of the clipped kidney and failure of the CLK to increase its GFR. Thromboxane (Tx) production by isolated perfused CLK was significantly elevated, whereas prostacyclin production remained unchanged. Furthermore, CLK GFR was inversely proportional to Tx production. Treatment of 4-wk hypertensive animals with either the Tx synthase inhibitor UK-38,485 or the Tx receptor antagonist GR 32191 produced a significant increase in CLK GFR. In addition, treatment with either the Tx synthase inhibitor or the Tx receptor antagonist significantly reduced systemic blood pressure. Thus, in this 2K, 1C model of hypertension, increased renal Tx production prevents functional hypertrophy of the contralateral kidney. As a result, CLK pressure-volume regulation is impaired and systemic hypertension is maintained. Furthermore, Tx antagonists restore CLK function and acutely lower systemic blood pressure. Therefore, increased renal Tx production by the CLK appears to be an important mediator of hypertension in the 2K, 1C model.

    Topics: 6-Ketoprostaglandin F1 alpha; Animals; Biphenyl Compounds; Blood Pressure; Glomerular Filtration Rate; Heptanoic Acids; Hypertension, Renovascular; Imidazoles; Kidney; Male; Rats; Rats, Inbred Strains; Receptors, Prostaglandin; Receptors, Thromboxane; Reference Values; Regional Blood Flow; Renal Circulation; Thromboxane B2; Thromboxane-A Synthase; Thromboxanes

1989